LifeMine Therapeutics

LifeMine Therapeutics is a company founded in 2018 headquartered in the United States. Its most recent tracked round is Series C+. Brouky classifies it under Healthcare & Life Sciences. Brouky records 1 investor associated with the company.

LifeMine Therapeutics is a biopharmaceutical company that leverages a unique, genomically-enabled drug discovery platform to identify and develop novel therapeutic molecules from eukaryotic microbes, with an initial focus on fungi. The company uses its Avatar™ platform, which integrates genomics, data science, synthetic biology, and AI to unlock nature's evolutionary wisdom for drug candidates targeting high-impact disease areas such as cancer, immune disorders, and rare diseases.